Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 10/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522284 | 1.00 | F9 (0.37) | F9TACR1FFAR4CCR2AKR1C3 | |
| SCHEMBL1439301 | 1.00 | F9 (0.37) | F9TACR1FFAR4CCR2AKR1C3 | |
| SCHEMBL1439298 | 1.00 | F9 (0.37) | F9TACR1FFAR4CCR2AKR1C3 | |
| SCHEMBL1438151 | 0.90 | F9 (0.35) | F9TACR1 | |
| SCHEMBL1438149 | 0.90 | F9 (0.35) | F9TACR1 | |
| SCHEMBL1438152 | 0.90 | F9 (0.35) | F9TACR1 | |
| SCHEMBL1949492 | 0.89 | F9 (0.42) | F9CCR2AKR1C3PPARDPPARA | |
| SCHEMBL1949488 | 0.89 | F9 (0.42) | F9CCR2AKR1C3PPARDPPARA | |
| SCHEMBL12546516 | 0.86 | F9 (0.36) | F9 | |
| SCHEMBL12546905 | 0.85 | F9 (0.38) | F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885TACR1 4149/4885FFAR4 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.